Guideline registry — generalized anxiety disorder¶
A catalogue of clinical practice guidelines and formal recommendation documents relevant to GAD worldwide. This file records documents. The synthesis of what they recommend, and where they disagree, is in wiki/guidelines.md.
Every PMID was retrieved live from PubMed on 2026-09-02; the NICE record was retrieved by HTTP request on the same date. Documents that could not be verified are marked as such rather than described from memory.
Master table¶
| # | Body | Year | Region | Scope | Citation / identifier | Status |
|---|---|---|---|---|---|---|
| 1 | WFSBP Task Force | 2023 | Global (33 experts, 22 countries) | Anxiety disorders incl. GAD — medications, psychotherapies and other non-pharmacological interventions; 1,007 RCTs evaluated | Bandelow B, et al. World J Biol Psychiatry. 2023;24:79-117. PMID 35900161 | Current (Version 3, Part I) |
| 2 | WFSBP Task Force | 2023 | Global (34 experts, 22 countries) | OCD (291 RCTs) and PTSD (234 RCTs) | Bandelow B, et al. World J Biol Psychiatry. 2023;24:118-134. PMID 35900217 | Current (Version 3, Part II) — out of scope for GAD, listed for completeness |
| 3 | WFSBP Task Force | 2008 | Global (30 experts) | Pharmacological treatment of anxiety, OCD and PTSD; 510 RCTs | Bandelow B, et al. World J Biol Psychiatry. 2008;9:248-312. PMID 18949648 | Superseded by → #1/#2; its abstract identifies it as an update of the 2002 guideline |
| 4 | NICE | 2011, updated 2020 | England and Wales | GAD and panic disorder in adults: stepped-care management | NICE CG113. Published 26 January 2011; last updated 15 June 2020. https://www.nice.org.uk/guidance/cg113 (accessed 2026-09-02) | Current |
| 5 | NICE (summary) | 2011 | England and Wales | BMJ summary of the CG113 recommendations | Kendall T, et al. BMJ. 2011;342:c7460. PMID 21270081 | Companion to #4 |
| 6 | British Association for Psychopharmacology | 2014 | UK | Evidence-based pharmacological treatment of anxiety disorders, PTSD and OCD — recognition, acute and longer-term treatment, combination, non-responders | Baldwin DS, et al. J Psychopharmacol. 2014;28:403-39. PMID 24713617 | Current BAP position |
| 7 | British Association for Psychopharmacology | 2005 | UK | First BAP anxiety-disorder guideline | Baldwin DS, et al. J Psychopharmacol. 2005;19:567-96. PMID 16272179 | Superseded by → #6 |
| 8 | German S3 (multi-society) | 2019 revision; report published 2022 | Germany | First revision of the anxiety-disorder guideline; 92 additional RCTs reviewed beyond the original 403 | Bandelow B, et al. Eur Arch Psychiatry Clin Neurosci. 2022;272:571-582. PMID 34609587 | Current revision located in this audit; retains CBT and SSRIs/SNRIs as first-line and recommends 6–12 months' medication continuation |
| 9 | German (GAD-focused review of the S3 evidence) | 2013 | Germany | Diagnosis and treatment of GAD specifically | Bandelow B, et al. Dtsch Arztebl Int. 2013;110:300-9. PMID 23671484 | Companion to #8 |
| 10 | Canadian expert consensus (Katzman et al.) | 2014 | Canada | Anxiety, PTSD and OCD; 10 sections including a dedicated GAD section, special populations and comorbidity | Katzman MA, et al. BMC Psychiatry. 2014;14 Suppl 1:S1. PMID 25081580 | Current Canadian anxiety guideline |
| 11 | Canadian Psychiatric Association | 2006 | Canada | Management of anxiety disorders | Can J Psychiatry. 2006;51:9S-91S. PMID 16933543 | Superseded by → #10 |
| 12 | CANMAT | 2025 (2024 guideline) | Canada | Perinatal mood, anxiety and related disorders — 10 clinical sections; medication safety evidence prioritised from large observational studies because RCT data are absent | Vigod SN, et al. Can J Psychiatry. 2025;70:429-489. PMID 39936923 | Current |
| 13 | CANMAT task force | 2012 | Canada | Mood disorders with comorbid anxiety disorders | Schaffer A, et al. Ann Clin Psychiatry. 2012;24:6-22. PMID 22303519 | Current for its niche; not updated in this search |
| 14 | Brazilian Psychiatric Association | 2024 | Brazil | GAD-specific: pharmacological and psychotherapeutic approaches; 59 studies selected from 4,860 | Baldaçara L, et al. Braz J Psychiatry. 2024;46:e20233235. PMID 37956131 | Current |
| 15 | AACAP | 2020 | United States | Assessment and treatment of children and adolescents with anxiety disorders | Walter HJ, et al. J Am Acad Child Adolesc Psychiatry. 2020;59:1107-1124. PMID 32439401 | Current |
| 16 | USPSTF | 2023 | United States | Screening for anxiety disorders in adults, including pregnant and postpartum persons | JAMA. 2023;329:2163-2170. PMID 37338866 | Current — B recommendation; I statement for adults ≥65 |
| 17 | USPSTF (evidence report) | 2023 | United States | Benefits and harms of screening and treatment; accuracy of instruments | O'Connor EA, et al. JAMA. 2023;329:2171-2184. PMID 37338868 | Evidence base for #16 |
| 18 | USPSTF | 2022 | United States | Screening for anxiety in children and adolescents | JAMA. 2022;328:1438-1444. PMID 36219403 | Current — B recommendation ages 8–18; I statement ≤7 |
| 19 | Women's Preventive Services Initiative (evidence review) | 2020 | United States | Screening for anxiety in adolescent girls and adult women | Nelson HD, et al. Ann Intern Med. 2020;173:29-41. PMID 32510989 | Evidence review; found no studies of overall screening effectiveness or harms |
| 20 | WFSBP + CANMAT taskforce | 2022 | Global (31 academics, 15 countries) | Nutraceuticals and phytoceuticals in psychiatric disorders, graded Recommended → Not Recommended | Sarris J, et al. World J Biol Psychiatry. 2022;23:424-455. PMID 35311615 | Current; updates 2015 guidance |
| 21 | Psychopharmacology Algorithm Project, Harvard South Shore | 2025 | United States | Stepwise pharmacological algorithm for GAD in older adults | Chen A, et al. J Geriatr Psychiatry Neurol. 2025;38:155-171. PMID 39352792 | Current; an algorithm, not a society guideline |
| 22 | Andalusian health service (ADAPTE method) | 2020 | Spain (Málaga) | GAD in primary care and mental health; 49 recommendations, 47 taken from NICE 2011 | Hurtado MM, et al. Int J Qual Health Care. 2020;32:356-363. PMID 32427320 | Current local adaptation; documents dependence on #4 |
| 23 | International Consensus Group on Depression and Anxiety | 2001 | Global | Consensus statement on GAD | Ballenger JC, et al. J Clin Psychiatry. 2001;62 Suppl 11:53-8. PMID 11414552 | Historical |
| 24 | Baldwin (evidence-based reviews used as de facto guidance) | 2005; 2011 | UK/international | Evidence-based pharmacotherapy of GAD | Baldwin DS, et al. Int J Neuropsychopharmacol. 2005;8:293-302. PMID 15576000; and 2011;14:697-710. PMID 21211105 | Historical; the 2011 paper supersedes the 2005 |
| 25 | American Psychiatric Association | 1998 | United States | Practice guideline for panic disorder (Work Group on Panic Disorder) | Am J Psychiatry. 1998;155:1-34. PMID 9585731 | Historical; no current APA practice guideline for GAD was located on PubMed on 2026-09-02 |
| 26 | Deprescribing guideline (Canadian, GRADE-based) | 2018 | Canada | Deprescribing benzodiazepine receptor agonists | Pottie K, et al. Can Fam Physician. 2018;64:339-351. PMID 29760253 | Current; explicitly does not apply to people with untreated anxiety |
Selected entries in detail¶
#1 WFSBP Version 3, Part I (2023) — the most methodologically ambitious¶
A consensus panel of 33 international experts from 22 countries evaluated 1,007 RCTs covering medications, psychotherapy and other non-pharmacological interventions in adults, adolescents and children, applying to psychotherapy the same assessment rigour normally reserved for drugs. Covers panic/agoraphobia, GAD, social anxiety disorder, specific phobias, mixed anxiety disorders in children and adolescents, separation anxiety and selective mutism. SSRIs and SNRIs are first-line medications; CBT is first-line psychotherapy. The panel also made explicit recommendations against interventions with insufficient evidence — an unusual and useful feature (PMID 35900161).
#4 NICE CG113 (2011, updated 2020) — the most operationally detailed, and the most copied¶
Structured as stepped care for GAD and panic disorder in adults. Verified live: published 26 January 2011, last updated 15 June 2020 (https://www.nice.org.uk/guidance/cg113, accessed 2026-09-02). Its downstream influence is documented rather than assumed: a Spanish guideline built with the ADAPTE method took 47 of its 49 recommendations directly from NICE 2011, adapted seven to the Spanish context and excluded three (Hurtado 2020, PMID 32427320).
#8/#9 German S3 and first revision — sequencing and duration¶
The original multi-society guideline evaluated 403 RCTs. Its first revision, developed from 2019 and published in 2022, added 92 RCTs and retained CBT and SSRIs/SNRIs as first-line options (PMID 34609587). The original report states that anxiety disorders should be treated with psychotherapy, drugs, or both; response to initial treatment is 45–65%; CBT has higher-level evidence than any other psychotherapy; psychodynamic therapy is recommended second-line; SSRIs and SNRIs are first choice; patient preference should be considered; drug treatment should continue 6–12 months after remission; if one modality is inadequately effective, switch to the other or combine (PMID 25138725). The GAD-focused companion adds response ranges of 47–75% for CBT and 44–81% for drugs (PMID 23671484).
#10 Katzman 2014 (Canada) — the broadest coverage of special situations¶
Developed by consensus, searching MEDLINE, PsycINFO and manual sources 1980–2012, with treatment strategies rated for strength of evidence and a clinical recommendation for each intervention. Ten sections including a dedicated GAD section plus sections on children/adolescents, pregnant and lactating women, the elderly, and comorbidity (PMID 25081580).
#16–#19 The screening documents — a recommendation without a screening trial¶
The USPSTF recommends screening adults, including pregnant and postpartum persons (B, moderate certainty of moderate net benefit) and children aged 8–18 (B), with I statements for adults ≥65 and children ≤7 (PMID 37338866; PMID 36219403). The supporting evidence report found that only two studies evaluated screening itself and neither found benefit; the recommendation rests on instrument accuracy plus the separate evidence that treatment works (PMID 37338868). The 2020 WPSI review reached the same structural conclusion: "No studies evaluated the overall effectiveness or harms of screening" (PMID 32510989). The late-life I statement drew a published objection arguing that late-life anxiety is under-studied rather than absent (Andreescu 2023, PMID 36652241).
#21 Harvard South Shore algorithm (2025) — the only explicit stepwise sequence located¶
SSRI first (sertraline or escitalopram preferred; buspirone if sexual side effects must be avoided) → a different SSRI or venlafaxine/duloxetine → pregabalin/gabapentin, lavender oil or agomelatine → quetiapine. Caution with benzodiazepines and hydroxyzine. Low priority but some support: vilazodone, vortioxetine, mirtazapine, cannabidiol. Notes that many older patients were started on benzodiazepines decades earlier and need periodic benefit–harm review (PMID 39352792).
Disagreements and gaps¶
| Issue | Positions held by different documents | Status |
|---|---|---|
| Benzodiazepines | German/Bandelow: effective short-term, not long-term, addiction risk (PMID 23671484). Brazilian: listed among indicated treatments (PMID 37956131). Harvard South Shore: caution in older adults with periodic review (PMID 39352792). Canadian deprescribing guideline: taper for all ≥65 regardless of duration — but explicitly not for untreated anxiety (PMID 29760253) | Unresolved. The disagreement tracks whether the measured outcome is trial dropout or long-term dependence |
| Pregabalin's line of therapy | WFSBP 2008 listed pregabalin among first-line agents alongside SSRIs/SNRIs (PMID 18949648); most current guidelines place it second-line; a 2025 meta-analysis argues for first-line status on efficacy, tolerability and cost-effectiveness (Cardoner 2025, PMID 39989902) | Contested |
| Quetiapine | Largest mean HAM-A estimate in the reference network but poorly tolerated; the Brazilian guideline discusses it, the Harvard algorithm places it fourth, and an umbrella review finds no high-quality antipsychotic evidence in anxiety outside quetiapine in GAD (Garakani 2024, PMID 38382649) | Evidence and positioning remain contested; harms restrict use |
| Screening asymptomatic adults | USPSTF B recommendation vs an evidence report finding no screening trial with benefit (PMID 37338866 vs 37338868) | The clearest internal tension in the guideline set |
| Treatment duration after remission | German S3: 6–12 months (PMID 25138725). Positive relapse-prevention trials ran 24–76 weeks (escitalopram) and 26 weeks (duloxetine, agomelatine) | Guidance is shorter than the longest positive trials; no document addresses indefinite treatment |
| Psychodynamic therapy | German S3 recommends second-line (PMID 25138725); most other guidelines are silent | Country-dependent |
| Nutraceuticals | A dedicated international guideline exists (PMID 35311615) but mainstream GAD guidelines do not incorporate it | Parallel, unintegrated stream |
Structural gaps, stated positively and dated 2026-09-02:
- No current American Psychiatric Association guideline for GAD. A PubMed search on 2026-09-02 located an APA practice guideline for panic disorder from 1998 (PMID 9585731) and no GAD guideline. For a disorder with a US lifetime prevalence of ~6% this is a conspicuous absence.
- No guideline engages the excessiveness dispute. The published case for deleting the criterion (Ruscio 2024, PMID 39364896) has no counterpart in any recommendation document catalogued here.
- Implementation of treatment-resistance criteria remains unsettled. A 2024 trans-anxiety Delphi consensus supplies operational recommendations and a potential staging model (PMID 38214637), but GAD-specific validation and uptake in guidelines remain limited.
- No guideline stratifies by comorbid depression, which is the commonest clinical presentation.
- Guideline dependency is undocumented. The Spanish ADAPTE exercise shows one national guideline being 96% NICE by content (PMID 32427320); nobody has mapped how much of global GAD guidance descends from a single 2011 document.
Watch list¶
| What to watch | Why | Next check |
|---|---|---|
| Next German S3 update | The first revision was published in 2022 and therefore predates the 2024 psychotherapy network and 2025 Cochrane antidepressant review | Next sweep |
| NICE CG113 | Last updated 15 June 2020; predates Papola 2024, Kopcalic 2025, Aktürk 2025 and the digital-CBT trials | Next sweep — check the NICE page's "Last updated" field directly |
| Any APA GAD guideline | Currently absent | Next sweep |
| MM120 phase 3 readouts (NCT06809595, NCT06741228) | A positive result would be the first new mechanism in GAD guidance since pregabalin | On publication |
| Benzodiazepine positioning | The 2025 within-class network (Fernandes 2025, PMID 40544830) is more favourable than guideline language; watch whether any body revises | Next sweep |
| Pregabalin line of therapy | Cardoner 2025 (PMID 39989902) argues first-line | Next sweep |
| ICD-11 operational guidance | ICD-11 GAD has no excessiveness requirement and no fixed symptom count (Domschke 2025, PMID 40728738); guidelines still describe DSM-shaped GAD | Next sweep |
Last curated: 2026-09-02.